DK1411926T3 - Integrininhibitorer til behandling af öjensygdomme - Google Patents

Integrininhibitorer til behandling af öjensygdomme

Info

Publication number
DK1411926T3
DK1411926T3 DK02748841T DK02748841T DK1411926T3 DK 1411926 T3 DK1411926 T3 DK 1411926T3 DK 02748841 T DK02748841 T DK 02748841T DK 02748841 T DK02748841 T DK 02748841T DK 1411926 T3 DK1411926 T3 DK 1411926T3
Authority
DK
Denmark
Prior art keywords
treatment
eye diseases
integrin inhibitors
integrin
inhibitors
Prior art date
Application number
DK02748841T
Other languages
English (en)
Inventor
Hans Markus Bender
Jutta Haunschild
Ulrich Lang
Matthias Wiesner
Martin Friedlander
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of DK1411926T3 publication Critical patent/DK1411926T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/5381,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/10Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK02748841T 2001-08-01 2002-07-03 Integrininhibitorer til behandling af öjensygdomme DK1411926T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30885101P 2001-08-01 2001-08-01
PCT/EP2002/007377 WO2003013511A1 (en) 2001-08-01 2002-07-03 Integrin inhibitors for the treatment of eye diseases

Publications (1)

Publication Number Publication Date
DK1411926T3 true DK1411926T3 (da) 2005-08-29

Family

ID=23195644

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02748841T DK1411926T3 (da) 2001-08-01 2002-07-03 Integrininhibitorer til behandling af öjensygdomme

Country Status (20)

Country Link
US (2) US20040198644A1 (da)
EP (1) EP1411926B1 (da)
JP (1) JP2005504757A (da)
KR (1) KR20040028966A (da)
CN (1) CN1536998A (da)
AR (1) AR036199A1 (da)
AT (1) ATE296628T1 (da)
AU (1) AU2002319282B2 (da)
BR (1) BR0211604A (da)
CA (1) CA2456076C (da)
DE (1) DE60204466T2 (da)
DK (1) DK1411926T3 (da)
ES (1) ES2243744T3 (da)
HU (1) HUP0401605A3 (da)
MX (1) MXPA04000839A (da)
PL (1) PL207175B1 (da)
PT (1) PT1411926E (da)
RU (1) RU2311177C2 (da)
WO (1) WO2003013511A1 (da)
ZA (1) ZA200401598B (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US7198795B2 (en) * 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
AU2003210517A1 (en) 2002-02-04 2003-09-02 Elan Pharma International, Ltd. Drug nanoparticles with lysozyme surface stabiliser
RU2007139541A (ru) * 2005-04-22 2009-05-27 Вайет (Us) Производные хромана и хромена и их применение
AU2008321770B2 (en) 2007-11-16 2012-09-06 Ube Industries, Ltd. Benzazepinone compound
EP2415474B1 (en) * 2009-03-30 2013-08-28 Ube Industries, Ltd. Pharmaceutical composition for treatment or prevention of ophthalmic diseases
WO2011106702A2 (en) 2010-02-25 2011-09-01 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
WO2012109363A2 (en) 2011-02-08 2012-08-16 The Johns Hopkins University Mucus penetrating gene carriers
WO2013138346A1 (en) 2012-03-16 2013-09-19 The Johns Hopkins University Non-linear multiblock copolymer-drug conjugates for the delivery of active agents
AU2013232297B2 (en) 2012-03-16 2016-01-14 The Johns Hopkins University Controlled release formulations for the delivery of HIF-1 inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9533068B2 (en) 2012-05-04 2017-01-03 The Johns Hopkins University Drug loaded microfiber sutures for ophthalmic application
US20150119792A1 (en) * 2012-05-08 2015-04-30 The Regents Of The University Of California Light degradable drug delivery system for ocular therapy
US10568975B2 (en) 2013-02-05 2020-02-25 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
CA2905242C (en) 2013-03-15 2016-11-29 Pfizer Inc. Indole compounds that activate ampk
EP3250184A1 (en) 2015-01-27 2017-12-06 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
KR101748120B1 (ko) * 2015-07-13 2017-06-16 서울대학교산학협력단 나노입자-유리체 기반 단백질 복합체를 유효성분으로 포함하는 혈관신생억제용 조성물 및 이의 용도
AU2016365312A1 (en) * 2015-12-04 2018-05-24 Janssen Biotech, Inc. Treatment of retinal degeneration using progenitor cells
MX2019005243A (es) * 2016-11-08 2019-08-05 Squibb Bristol Myers Co Derivados de indazol como antagonistas de integrina alfa v.
KR102307767B1 (ko) * 2019-03-11 2021-10-01 서울대학교병원 망막맥락막 신생혈관성 질환을 진단하기 위한 인테그린 αvβ3 표적화 프로브 및 이의 제조 방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU726793B2 (en) * 1995-08-14 2000-11-23 Scripps Research Institute, The Methods and compositions useful for inhibition of alpha v beta 5 mediated angiogenesis
DE19538741A1 (de) * 1995-10-18 1997-04-24 Merck Patent Gmbh Cyclopeptidderivate
US5904144A (en) * 1996-03-22 1999-05-18 Cytotherapeutics, Inc. Method for treating ophthalmic diseases
JP2002515036A (ja) * 1996-05-31 2002-05-21 ザ スクリップス リサーチ インスティテュート α▲下V▼β▲下5▼媒介血管形成の抑制に有用な方法および組成物
SK163298A3 (en) * 1996-05-31 1999-07-12 Scripps Research Inst Methods and compositions useful for inhibition of 'alpha'v'beta'5 mediated angiogenesis
DE19705450A1 (de) * 1997-02-13 1998-08-20 Merck Patent Gmbh Bicyclische aromatische Aminosäuren
US6255353B1 (en) * 1998-03-13 2001-07-03 Centaur Pharmaceuticals, Inc. Inhibition of angiogenesis
US6489305B1 (en) * 1998-05-08 2002-12-03 Canji, Inc. Methods and compositions for the treatment of ocular diseases
US6378526B1 (en) * 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
DE19850131A1 (de) * 1998-10-30 2000-05-04 Merck Patent Gmbh Chromenon- und Chromanonderivate
DE10006139A1 (de) * 2000-02-11 2001-08-16 Merck Patent Gmbh Indol-3-yl-Derivate

Also Published As

Publication number Publication date
EP1411926A1 (en) 2004-04-28
AU2002319282B2 (en) 2007-06-28
RU2004106527A (ru) 2005-07-10
US20040198644A1 (en) 2004-10-07
EP1411926B1 (en) 2005-06-01
US20060287225A1 (en) 2006-12-21
CN1536998A (zh) 2004-10-13
WO2003013511A1 (en) 2003-02-20
ES2243744T3 (es) 2005-12-01
DE60204466T2 (de) 2006-04-27
BR0211604A (pt) 2004-08-24
HUP0401605A3 (en) 2012-09-28
CA2456076C (en) 2011-08-23
PL207175B1 (pl) 2010-11-30
HUP0401605A2 (hu) 2004-11-29
PT1411926E (pt) 2005-10-31
DE60204466D1 (de) 2005-07-07
ATE296628T1 (de) 2005-06-15
US7645736B2 (en) 2010-01-12
ZA200401598B (en) 2004-11-17
PL367959A1 (en) 2005-03-07
MXPA04000839A (es) 2004-05-14
CA2456076A1 (en) 2003-02-20
KR20040028966A (ko) 2004-04-03
JP2005504757A (ja) 2005-02-17
AR036199A1 (es) 2004-08-18
RU2311177C2 (ru) 2007-11-27

Similar Documents

Publication Publication Date Title
DK1411926T3 (da) Integrininhibitorer til behandling af öjensygdomme
DK1575597T3 (da) Anvendelse af rimexolon til behandling af öjentörhed
IS7215A (is) Aðferðir til að meðhöndla nýæðarsjúkdóma í augum
DK1944322T3 (da) Behandling af TNFalfa-relaterede sygdomme
DK1446122T5 (da) Anvendelse af flibanserin til behandling af uregelmæssigheder ved könsdriften
DK2308507T3 (da) Fremgangsmåder til behandling af præeklampsi
DK1803718T3 (da) 4-Tetrazolyl-4-phenylpiperidin-derivater til behandling af smerter
DK1762567T3 (da) Pyrazolderivater til behandling af HIV
NO20035609D0 (no) Fremgangsmåte for kontinuerlig naftabehandling
DK1509121T3 (da) Okulærvisningsapparat til behandling af øjenlidelser
NO20035156L (no) Fremgangsmåter for brønnbehandling
DK1343773T3 (da) Thiazolderivater til behandling af PPAR-beslægtede forstyrrelser
DK1448205T3 (da) Kombinationer til behandling af immunoinflammatoriske sygdomme
DK1392318T3 (da) 15-keto-prostaglandiner til behandling af lægemiddelinduceret forstoppelse
NO20035224D0 (no) Oftalmisk pirenzepingel
DK1516596T3 (da) Forbedret system til behandling af stress-urinkontinens
DK1381382T3 (da) Fremgangsmåder og præparater til behandling af öjensygdomme
NO20034123L (no) Fremgangsmåte for behandling av brennstoff
DK1727801T3 (da) Til behandling af smerter anvendelige piperaziner
DE60200302D1 (de) Laseraugenbehandlungseinrichtung
DK1268482T3 (da) Pyranoindoler til behandling af glaukom
NO20042613L (no) Ny anvendelse for behandling av gastroosofagial refluks
DK1309322T3 (da) Anvendelse af 3-benzoylphenyleddikesyrederivater til behandling af retinale lidelser
DK1400522T3 (da) Forbindelser til behandling af impotens
DK1289945T3 (da) Anilindisulfidderivater til behandling af allergiske sygdomme